Tags

Type your tag names separated by a space and hit enter

Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy.
BMC Cancer 2019; 19(1):483BC

Abstract

BACKGROUND

The relationship between polymorphisms in vascular endothelial growth factor (VEGF) and gastric cancer is still inconclusive. We investigated whether there is an association between VEGF genetic polymorphisms and risk of gastric cancer, and evaluated the recurrence of advanced gastric cancer after curative resection with adjuvant chemotherapy according to VEGF genetic polymorphisms.

METHODS

The association of functional single nucleotide polymorphisms (SNPs) of the VEGF gene (+936C > T, - 634G > C, - 2578C > A, + 1612G > A) were evaluated. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. A total of 151 patients with gastric cancer were enrolled, and the control group consisted of 413 individuals with esophago-gastroduodenoscopy who were randomly selected through health screening. All of the enrolled patients had curative resections with completion of adjuvant capecitabine and oxaliplatin combination chemotherapy and the initial metastatic cases were excluded. During the regular follow-up protocol, the episodes of the recurrence were documented and the specific genotype and allelic frequencies were evaluated.

RESULTS

As for the cancer risk, there were no significant differences in specific genotypes and allelic frequencies. The mean follow-up period was 28.82 ± 30.92 (12 ~ 72) months and the recurrence rate was 28.3%. In the patients carrying the 936-C allele, the recurrence rate of gastric cancer was high (P = 0.02). Disease-free interval was significantly different between the patients carrying the 936-CC and 936-CT/TT genotype (P = 0.02).

CONCLUSIONS

VEGF 936-C allele is associated with poor prognosis, but not risk of gastric cancer. In the patients carrying the 936-C allele, more potent adjuvant treatment would be considered.

Authors+Show Affiliations

Division of Gastroenterology, Department of Internal Medicine, St. Vincent's Hospital,, The Catholic University of Korea, 93-6 Jungbu-daero, Paldal-gu, Suwon, Republic of Korea.Division of Gastroenterology, Department of Internal Medicine, St. Vincent's Hospital,, The Catholic University of Korea, 93-6 Jungbu-daero, Paldal-gu, Suwon, Republic of Korea. jwchulkr@catholic.ac.kr.Department of Surgery, St. Vincent's Hospital, The Catholic University of Korea, 93-6 Jungbu-daero, Paldal-gu, Suwon, Republic of Korea.Department of Surgery, St. Vincent's Hospital, The Catholic University of Korea, 93-6 Jungbu-daero, Paldal-gu, Suwon, Republic of Korea.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31117964

Citation

Kim, Yeon-Ji, et al. "Genetic Polymorphisms of Vascular Endothelial Growth Factor (VEGF) Associated With Gastric Cancer Recurrence After Curative Resection With Adjuvant Chemotherapy." BMC Cancer, vol. 19, no. 1, 2019, p. 483.
Kim YJ, Chung WC, Jun KH, et al. Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy. BMC Cancer. 2019;19(1):483.
Kim, Y. J., Chung, W. C., Jun, K. H., & Chin, H. M. (2019). Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy. BMC Cancer, 19(1), p. 483. doi:10.1186/s12885-019-5702-5.
Kim YJ, et al. Genetic Polymorphisms of Vascular Endothelial Growth Factor (VEGF) Associated With Gastric Cancer Recurrence After Curative Resection With Adjuvant Chemotherapy. BMC Cancer. 2019 May 22;19(1):483. PubMed PMID: 31117964.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy. AU - Kim,Yeon-Ji, AU - Chung,Woo Chul/, AU - Jun,Kyong-Hwa, AU - Chin,Hyung-Min, Y1 - 2019/05/22/ PY - 2018/01/31/received PY - 2019/05/10/accepted PY - 2019/5/24/entrez PY - 2019/5/24/pubmed PY - 2019/5/24/medline KW - Gastric cancer KW - Polymorphism KW - Prognosis KW - VEGF SP - 483 EP - 483 JF - BMC cancer JO - BMC Cancer VL - 19 IS - 1 N2 - BACKGROUND: The relationship between polymorphisms in vascular endothelial growth factor (VEGF) and gastric cancer is still inconclusive. We investigated whether there is an association between VEGF genetic polymorphisms and risk of gastric cancer, and evaluated the recurrence of advanced gastric cancer after curative resection with adjuvant chemotherapy according to VEGF genetic polymorphisms. METHODS: The association of functional single nucleotide polymorphisms (SNPs) of the VEGF gene (+936C > T, - 634G > C, - 2578C > A, + 1612G > A) were evaluated. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. A total of 151 patients with gastric cancer were enrolled, and the control group consisted of 413 individuals with esophago-gastroduodenoscopy who were randomly selected through health screening. All of the enrolled patients had curative resections with completion of adjuvant capecitabine and oxaliplatin combination chemotherapy and the initial metastatic cases were excluded. During the regular follow-up protocol, the episodes of the recurrence were documented and the specific genotype and allelic frequencies were evaluated. RESULTS: As for the cancer risk, there were no significant differences in specific genotypes and allelic frequencies. The mean follow-up period was 28.82 ± 30.92 (12 ~ 72) months and the recurrence rate was 28.3%. In the patients carrying the 936-C allele, the recurrence rate of gastric cancer was high (P = 0.02). Disease-free interval was significantly different between the patients carrying the 936-CC and 936-CT/TT genotype (P = 0.02). CONCLUSIONS: VEGF 936-C allele is associated with poor prognosis, but not risk of gastric cancer. In the patients carrying the 936-C allele, more potent adjuvant treatment would be considered. SN - 1471-2407 UR - https://www.unboundmedicine.com/medline/citation/31117964/Genetic_polymorphisms_of_vascular_endothelial_growth_factor_(VEGF)_associated_with_gastric_cancer_recurrence_after_curative_resection_with_adjuvant_chemotherapy L2 - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5702-5 DB - PRIME DP - Unbound Medicine ER -